Bioequivalence of Phenazopyridine HCl in Healthy Volunteers

Human Volunteers Clinical Trial

Official title:

2 Treatment, 2 Period, Randomized, Single Blinded, Crossover Bioequivalence of Phenazopyridine HCl in 24 Healthy Volunteers

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT00743977
• Other study ID #: URG/STEROP/001
• Status: Unknown status
• Phase: N/A
• First received: August 28, 2008
• Last updated: August 28, 2008
• Start date: August 2008

Study information

• Verified date: August 2008
• Source: Universal Enterprises
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study aims at comparing the pharmacokinetics of the original formulation of phenazopyridine and a same generic product.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 24
• Est. primary completion date: November 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy subjects aged 18 to 55 (Male & Female)

• Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests

• Informed consent signed by the subject

• The subject is co-operative and available for the entire study

• Not pregnant or nursing

• Normal renal and hepatic function

Exclusion Criteria:

• Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, hematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation

• Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma

• Evidence of hypertension (blood pressure after 3 minutes sitting>160/95 mm Hg)

• Evidence of chronic or acute infectious diseases;

• History or evidence of malignant tumors;

• Evidence of hyperuricaemia, elevated serum uric acid (>8.0 mg/dl)

• Hepatic or renal impairment; elevated serum creatinine (>1.4 mg/dl)

• Planned vaccination during the time course of the study

• Adherence to a diet (i.e, vegetarian) or life style (incl. extreme sports) that might interfere with the investigation

• Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, HCV antibody or HBs antigen testing

• Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription)

• Single use of any medication (including OTC) that are not expressively permitted within two weeks prior to start of the study

• Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day)

• Drug addiction

• Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 week

• Subjects who are known or suspected

• not to comply with the study directives

• not to be reliable or trustworthy

• not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed.

• to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.

Related Conditions & MeSH terms

• Human Volunteers

Intervention

Drug:
• Phenazopyridine HCl
100mg tablet in fasting state

Locations

Country	Name	City	State
Pakistan	Health Care Hospital	Karachi

Sponsors (1)

Lead Sponsor	Collaborator
Universal Enterprises

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine		regular intervals after drug dosing